4//SEC Filing
New Leaf Ventures II, L.P. 4
Accession 0000899243-19-021804
CIK 0001510487other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 4:47 PM ET
Size
18.2 KB
Accession
0000899243-19-021804
Insider Transaction Report
Form 4
New Leaf Ventures II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote)
New Leaf Venture Associates II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote)
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote)
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote)
New Leaf BPO Associates II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote)
New Leaf BPO Management II, L.L.C
10% Owner
Transactions
- Sale
Common Stock
2019-08-13$35.00/sh−250,009$8,750,315→ 1,938,167 total(indirect: See footnote) - Sale
Common Stock
2019-08-13$35.00/sh−49,991$1,749,685→ 387,546 total(indirect: See footnote)
Footnotes (4)
- [F1]These shares are held directly by New Leaf Ventures II, L.P. ("NLV-II"). The general partner of NLV-II is New Leaf Venture Associates II, L.P. ("NLVA-II"). The general partner of NLVA-II is New Leaf Venture Management II, L.L.C. ("Management-II"). Each of NLVA-II and Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-II or Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Each of Ronald M. Hunt and Vijay K. Lathi, the managers of Management-II (each, a "NLV-II Manager" and collectively, the "NLV-II Managers"), New Leaf Venture Partners, L.L.C. (together with its affiliates, "New Leaf Ventures"), may each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities.
- [F2]Each of the NLV-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. ("BPO-II"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Each of Ronald M. Hunt, Vijay K. Lathi and Isaac J. Manke, the managers of BPO Management-II (each, a "BPO-II Manager" and collectively, the "BPO-II Managers"), each, by virtue of their respective affiliations with and/or interests in New Leaf Ventures, be deemed to have shared voting and investment power with respect to these securities.
- [F4]Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
Principia Biopharma Inc.
CIK 0001510487
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001441439
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 4:47 PM ET
- Size
- 18.2 KB